Figure 28 is a forest plot depicting our meta-analysis on the percent of patients achieving remission based on the MADRS for depression, by dose. Four placebo controlled trials that evaluated the use of quetiapine at 150mg were pooled, resulting in a statistically significant pooled estimate of the relative risk of remission of 1.36. These same four placebo controlled trials also reported the use of quetiapine at 300mg. The 300mg quetiapine trials were pooled, resulting in a statistically significant pooled estimate of the relative risk of remission of 1.51. One trial evaluated quetiapine at 50mg, results were not statistically significant.

Figure 28Depression—MADRS % remitted—dose

From: Results

Cover of Off-Label Use of Atypical Antipsychotics: An Update
Off-Label Use of Atypical Antipsychotics: An Update [Internet].
Comparative Effectiveness Reviews, No. 43.
Maglione M, Maher AR, Hu J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.